RecruitingPhase 3NCT07128199
A Study to Assess Zipalertinib Versus Placebo in Participants With Early Stage NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection
Sponsor: Taiho Oncology, Inc.
Commack, NY · East White Plains, NY · Lake Success, NY · +27 more sites